Riverbed downgraded at Cantor from buy to hold, Cantor Fitzgerald said. $20 price target. Core products are showing little growth.
Teva (TEVA) downgraded at Canaccord to hold, Canaccord Genuity said. $45 price target. Company turnaround is taking longer than expected.
Trinity Industries (TRN) downgraded at UBS to neutral from buy, UBS said. $41 price target. Continued growth in tank car orders increasingly challenging.
Westlake Chemical (WLK) upgraded at UBS to neutral from sell, UBS said. $90 price target. Softer ethane pricing outlook.
STOCK COMMENTS / EPS CHANGES
Biogen Idec (BIIB) numbers increased at Credit Suisse. BIIB estimates were raised through 2016, Credit Suisse said. Tysabri deal should add to earnings. Outperform rating and new $185 price target. Cigna (CI) numbers raised at Jefferies. Shares of CI now seen reaching $71, Jefferies said. Estimates also raised on its upward 2013 revision. Buy rating. Cisco (CSCO) target raised at Citigroup to $24, Citigroup said. Continued execution in an improving macro environment. Buy rating. Coinstar (CSTR) estimates, target cut at JP Morgan. CSTR estimates were reduced through 2014, JP Morgan said. Company is seeing lower sales. Neutral rating and new $51 price target. Eastman Chemical (EMN) target raised at Jefferies. Shares of EMN now seen reaching $79, Jefferies said. Favorable pricing in 2013. Hold rating. Google (GOOG) added to Best Ideas List at Morgan Stanley. Company can deliver 15% compound annual free cash flow growth over the next five years. $932 price target. CarMax (KMX) numbers raised at Oppenheimer. Shares of KMX now seen reaching $46, Oppenheimer said. Estimates also raised on attractive market share growth. Outperform rating. LinkedIn (LNKD) estimates, target raised at BMO. Shares of LNKD now seen reaching $130, according to BMO Capital. Estimates also increased, as new products are driving growth. Market Perform rating. Microchip Technology (MCHP) numbers raised at Jefferies. Shares of MCHP now seen reaching $41, Jefferies said. Estimates also raised on fourth quarter beat. Buy rating. Microchip estimates, target raised at Credit Suisse. Shares of MCHP now seen reaching $40, according to Credit Suisse. Estimates also increased, as the company is seeing higher core demand and benefits from acquisitions. Outperform rating. Martin Marietta (MLM) numbers raised at Jefferies. Shares of MLM now seen reaching $114, Jefferies said. Estimates also raised stronger demand enabling fourth quarter beat. Buy rating. NCR (NCR) estimates, target boosted at JP Morgan. Shares of NCR now seen reaching $37, according to JP Morgan. Estimates also upped, given the company's new guidance. Overweight rating. OpenTable (OPEN) numbers lowered at Oppenheimer. Shares of OPEN now seen reaching $49, Oppenheimer said. Estimates also lowered on slowing earnings growth. Perform rating. Patterson-UTI (PTEN) numbers upped at BMO. PTEN estimates were boosted through 2014, BMO Capital said. Company is seeing higher demand for pressure pumping. Outperform rating and new $25 price target. >To submit a news tip, email: tips@thestreet.com.Follow TheStreet on Twitter and become a fan on Facebook.
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
